**CURRICULUM VITAE**

**Federica DI NICOLANTONIO, PhD**

SCOPUS- Author ID: [6603519922](https://www.scopus.com/authid/detail.uri?authorId=6603519922)

ORCID: [0000-0001-9618-2010](https://orcid.org/0000-0001-9618-2010)

ResearcherID: [A-2503-2011](http://www.researcherid.com/rid/A-2503-2011)

Google Scholar: <https://scholar.google.com/citations?user=KjvCAwgAAAAJ&hl=en>

Web: <https://deponcology.campusnet.unito.it/do/docenti.pl/Alias?federica.dinicolantonio>

<https://www.researchgate.net/profile/Federica_Di_Nicolantonio>

<http://www.ircc.it/?q=Cancer-Epigenetics>

Twitter: <https://twitter.com/fdinicolantonio>

* **CURRENT POSITIONS**

2018– Associate Professor in Biochemistry

Department of Oncology, University of Torino, Torino, Italy.

2015 – Group Leader, Laboratory of Cancer Epigenetics

Candiolo Cancer Institute – FPO, IRCCS, Torino, Italy.

* **PREVIOUS POSITIONS**

2016–2018 Senior Lecturer in Clinical Biochemistry and Clinical Molecular Biology

Department of Oncology, University of Torino, Torino, Italy.

2012 – 2016 Junior Lecturer in Clinical Biochemistry and Clinical Molecular Biology

Department of Oncology, University of Torino, Torino, Italy.

2012 – 2014 Junior Group Leader, Laboratory of Pharmacogenomics

Candiolo Cancer Institute – FPO, IRCCS, Torino, Italy.

* **EDUCATION and TRAINING**

2005 – 2011: Post-doctoral training, Candiolo Cancer Institute, IRCCS, Torino, Italy.

2003 – 2004: Research Associate, Queen Alexandra Hospital, University of Portsmouth, UK

2000 – 2004: Doctor of Philosophy in Medicine (Clinical Sciences), University College London. Thesis: Multidrug resistance in solid tumors http://discovery.ucl.ac.uk/1354622/

1999: PharmD, School of Pharmacy, University of Torino, Italy.

* **AWARDS and FELLOWSHIPS**

2018 – 2024 National scientific qualification for the calls in the role of full professor in Clinical Biochemistry and Molecular Biology

2014 – 2020 National scientific qualification for the calls in the role of associate professor in Biochemistry, Clinical Biochemistry and Molecular Biology

2011 Award, Andrea and Libi Lorini Foundation, Milan for the article Di Nicolantonio F et al., J Clin Oncol. 2008 Dec 10;26(35):5705-12

2010 – 2011 2-year-FIRC- Fellowship, IFOM-FIRC, Milan, Italy

* **SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS**

2013 – Five Postdocs, Two PhD Students, Five Master Students

Department of Oncology, University of Torino, Torino, Italy.

* **TEACHING ACTIVITIES**

2014 – Lecturer in Biochemistry and Molecular Biology– Medical School, University of Torino, Italy

2013 – Lecturer in Biochemistry – Nursing School, University of Torino, Italy

* **ORGANISATION OF SCIENTIFIC MEETINGS**

2018 AACR annual meeting, Program Committee member for session ‘Liquid Biopsies’

2015 AACR annual meeting, Program Committee member for session ‘Targeted Therapies’

2014 39th ESMO Congress Madrid meeting, Program Committee member for session ‘‘Gastrointestinal (colorectal) cancer’’ -

2013 AACR annual meeting, Abstract reviewer for sections CL13-01 Diagnostic/early detection biomarkers; CL13-02 Prognostic/ metastasis biomarkers; CL13-03 Biomarkers predictive of therapeutic benefit

2011 SIC – Italian Society for Cancerology – Annual Meeting, Torino. Member of the Local organizing committee.

* **INSTITUTIONAL RESPONSIBILITIES**

2017 – Member of the Executive Board, Department of Oncology, University of Torino, Italy

2016 –- 2018 Member of the Teaching Committee, Department of Oncology, University of Torino, Italy

2013 – Faculty Member of the PhD Programme in Molecular Medicine, University of Torino, Italy

2013 – Graduate Student Advisor, University of Torino, Italy

2012 – Scientific Committee Member, Fondazione Oncologia Ca’ Granda ONLUS (OCGO), Milan, Italy

* **REVIEWING ACTIVITIES**

2017 – Editorial Board, Molecular Cancer (IF = 7.776); BioMed Central

2011 – Associate Editor, Clinical Cancer Research (IF = 10.199), AACR

2011 – Review Editor, Frontiers in Oncology (IF = 4.416)

2010 – Editorial Board, BMC Cancer (IF = 3.288); BioMed Central

2018 Grant Reviewer, Belgian Fondation contre le Cancer

2015 – 2016 Grant Reviewer for National Institute of Health Carlos III

2016 Grant Reviewer for Swiss Cancer League

2015 – 2017 Grant Reviewer, ERC Starting Grant 2016

* **MEMBERSHIPS OF SCIENTIFIC SOCIETIES**

2002 – Member, American Association for Cancer Research (Member ID 88803);

AACR Associate member from 12 Dec 2002 to 18 Feb 2013;

AACR Active member since 19 Feb 2013

2014 – Member, European Association for Cancer Research (Member #3667)

2017 – Invited Member, Cancer Epigenetics Society (<https://ces.b2sg.org>)

**CURRENT FUNDING**

|  |  |
| --- | --- |
| Funding source | EU-TRANSCAN |
| Project Title | Early detection of relapses in stage III colon cancer patients by longitudinally following a personalized molecular signature from a a blood test: THRuST |
| Period | 01/04/2018 – 31/03/2021 |
| Role of the PI | Group Leader |
|  |  |
| Funding source | AIRC Investigator Grant (IG) n.17707 |
| Project Title | Resistance to BRAF combination therapies in BRAF mutant colorectal cancer |
| Period | 02/01/2016-01/07/2019 |
| Role of the PI | Coordinator |
|  |  |
| Funding source | AIRC Investigator Grant (IG) n.21407 |
| Project Title | Methylation based liquid biopsy to predict molecular residual disease and risk of recurrence in colon cancer patients |
| Period | 02/01/2019-31/12/2023 |
| Role of the PI | Coordinator |
|  |  |
| Funding source | AIRC Special Call 5x1000 Metastatic disease: the key unmet need in oncology 2018 |
| Project Title | Insights into the evolving heterogeneity of metastatic colorectal cancer: from mechanisms to therapies. Grant ID # 2109. |
| Period | 01/07/2018-30/06/2025 |
| Role of the PI | Group Leader |
|  |  |
| Funding source | FPRC 5x1000 |
| Project Title | Epigenetics of colorectal cancer |
| Period | 2018-2020 |
| Role of the PI | Group Leader |

**MAJOR RESEARCH ACHIEVEMENTS**

I have been active in cancer research for over 15 years, throughout which I have demonstrated an established record of accomplishments in the field of translational oncology. My research interests have always been inspired by the observation that the ‘one-size-fits-all’ approach should not be applied to treat cancers of the same histological type; since tumors affecting the same tissue often display individual and peculiar morphological and molecular features. My studies on the molecular mechanisms of cell transformation have been consistently aimed at identifying individualized targets amenable for therapeutic intervention as well as cancer prognostic and/or predictive biomarkers. First as a PhD student in Ian Cree’s laboratory at UCL (now in Lyon, France, as the Head of the WHO/IARC Classification of Tumours (WCT) group), then as a post-doctoral fellow in Alberto Bardelli’s lab, and finally as an independent investigator at the Candiolo Cancer Institute, I have shown that it is possible to deliver precision cancer medicine by coupling tumor molecular profiling with functional studies in clinically relevant preclinical models.

My research contributed to establish that activated RAS-BRAF signalling can by-pass EGFR targeted inhibition in metastatic colorectal cancer, a notion that led to restricting the use of EGFR targeted monoclonal antibodies to RAS wild-type metastatic colorectal cancer patients. In this regard, I am the leading author of a highly cited manuscript that first described BRAF V600E mutations as a biomarker of adverse prognosis and of resistance to EGFR targeted therapies in metastatic colorectal cancer patients (Di Nicolantonio F et al., J Clin Oncol. 2008 Dec 10;26(35):5705-12).

In the same field, I contributed as a co-first author to the discovery that lack of efficacy of BRAF inhibitors could be mediated by feedback re-activation EGFR in colon tumors, and proved that combinations of EGFR and BRAF inhibitors were effective in restraining growth of BRAF mutant colorectal cancer xenografts (Prahallad A\*, Sun C\*, Huang S\*, Di Nicolantonio F\*. (…) Bernards R. Nature. 2012; 483(7387):100-3). My publications in the field spurred several editorials and commentaries highlighting the clinical relevance of our results. More importantly, my preclinical works have also provided the rationale for the design of clinical trials testing BRAF and EGFR inhibitor combinations in BRAF mutant metastatic colorectal cancer patients. My laboratory has recently shown that it possible to individualize treatment of BRAF mutant metastatic colorectal cancer patients, by studying mechanisms of primary and acquired resistance to molecularly targeted agents in tumor samples as well as in liquid biopsies (Pietrantonio F., (…) Di Nicolantonio F. Cancer Discov. 2016 Sep;6(9):963-71 Oddo D., (…) Di Nicolantonio F. Cancer Res. 2016 Aug 1;76(15):4504-15).

I have lately developed an interest in epigenetics of colorectal cancer, since methylation changes can serve as tumor-specific changes for monitoring tumor burden in plasma circulating tumor DNA, as well as modifiers of drug response. In this regard, my team has implemented a digital PCR based assay to provide a quantitative assessment of MGMT methylation in tissue and liquid biopsies for prediction of response to alkylating agents in advanced CRC patients (Barault L., (…) Di Nicolantonio F. Ann Oncol. 2015;26(9):1994-9). As mentioned in this proposal, we have completed genome-wide assessment of DNA methylation of a collection of 149 colorectal cancer cell lines and compared it to normal mucosa and blood cells, in order to define a highly specific and sensitive gene methylation signature to be employed in liquid biopsy tests. We have evidence that assessment of methylated markers in cell-free circulating DNA allows non-invasive monitoring of disease burden in metastatic colorectal cancer patients. Methylation changes over time correlate with tumor response evaluated by CT-scan in patients treated with chemotherapy or targeted agents (Barault L., (…) Di Nicolantonio F Gut, 2018.).

***Publications***

I have co-authored more than 100 peer-reviewed publications in internationally recognized journals (H-index= 39). A complete list of publications can be found on:

<https://www.ncbi.nlm.nih.gov/pubmed/?term=Di+Nicolantonio+F>

Clarivate Analytics (formerly The Institute for Scientific Information (ISI), Philadelphia) has listed Dr. Di Nicolantonio as a 2018 Highly Cited researcher for her multidisciplinary research (<https://hcr.clarivate.com/#freeText%3DDi%20Nicolantonio>).

I am a member of the “Group 2003” that includes the most cited Italian scientists in different fields.

Selected publications

1. Corti G, Bartolini A, Crisafulli G, Novara L, Rospo G, Montone M, Negrino C, Mussolin B, Buscarino M, Isella C, Barault L, Siravegna G, Siena S, Marsoni S, **Di Nicolantonio F**, Medico E, Bardelli A. A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. Clin Colorectal Cancer. 2019 Mar 7. pii: S1533-0028(18)30588-7. doi: 10.1016/j.clcc.2019.02.008. PMID: 30981604 (**corresponding author**).
2. Rizzolio S, Cagnoni G, Battistini C, Bonelli S, Isella C, Van Ginderachter JA, Bernards R, **Di Nicolantonio F,** Giordano S, Tamagnone L. Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies. J Clin Invest. 2018 Aug 31;128(9):3976-3990. doi: 10.1172/JCI99257. Epub 2018 Aug 13. PMID: 29953416
3. Russo M, Lamba S, Lorenzato A, Sogari A, Corti G, Rospo G, Mussolin B, Montone M, Lazzari L, Arena S, Oddo D, Linnebacher M, Sartore-Bianchi A, Pietrantonio F, Siena S, **Di Nicolantonio F**, Bardelli A. Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. Nat Commun. 2018 Jun 12;9(1):2287. doi: 10.1038/s41467-018-04506-z. PubMed PMID: 29895949
4. Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello S, Scagliotti GV, **Di Nicolantonio, F\***, Taulli, R. Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. OncoImmunology, 2018; 7(3): Article: e1398874 **\*co-senior author and corresponding author**
5. Pietrantonio F, **Di Nicolantonio F\***, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Cremolini C. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089. \*co-senior author and corresponding author
6. Barault L, Amatu A, Siravegna G, Ponzetti A, Moran S, Cassingena A, Mussolin B, Falcomatà C, Binder AM, Cristiano C, Oddo D, Guarrera S, Cancelliere C, Bustreo S, Bencardino K, Maden S, Vanzati A, Zavattari P, Matullo G, Truini M, Grady WM, Racca P, Michels KB, Siena S, Esteller M, Bardelli A, Sartore-Bianchi A, **Di Nicolantonio F**. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut. 2018 Nov;67(11):1995-2005.. pii: gutjnl-2016-313372. doi: 10.1136/gutjnl-2016-313372.
7. Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, **Di Nicolantonio F**, Bardelli A. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673.
8. Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, Morano F, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fucà G, Lamba S, Martinetti A, Di Bartolomeo M, de Braud F, Bardelli A, Pietrantonio F, **Di Nicolantonio F**. Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. Br J Cancer. 2017 Jul 25;117(3):347-352. doi: 10.1038/bjc.2017.196. PMID: 28654634
9. Patients. Clin Cancer Res. 2017 Aug 1;23(15):4312-4322. doi: 10.1158/1078-0432.CCR-16-
10. Sartore-Bianchi A, Pietrantonio F, Amatu A, Milione M, Cassingena A, Ghezzi S, Caporale M, Berenato R, Falcomatà C, Pellegrinelli A, Bardelli A, Nichelatti M, Tosi F, De Braud F, **Di Nicolantonio F**, Barault L, Siena S. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. Eur J Cancer. 2017 Jan;71:43-50. doi: 10.1016/j.ejca.2016.10.032. Epub 2016 Dec 18. PMID: 27997874
11. Comunanza V, Corà D, Orso F, Consonni FM, Middonti E, **Di Nicolantonio F**, Buzdin A, Sica A, Medico E, Sangiolo D, Taverna D, Bussolino F. VEGF blockade enhances the antitumor effect of BRAFV600E inhibition. EMBO Mol Med. 2017 Feb;9(2):219-237. doi: 10.15252/emmm.201505774. PMID: 27974353
12. Pietrantonio F, Oddo D, Gloghini A, Valtorta E, Berenato R, Barault L, Caporale M, Busico A, Morano F, Gualeni AV, Alessi A, Siravegna G, Perrone F, Di Bartolomeo M, Bardelli A, de Braud F, **Di Nicolantonio F.** MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. Cancer Discov. 2016 Sep;6(9):963-71. doi: 10.1158/2159-8290.CD-16-0297. Epub 2016 Jun 20. PMID: 27325282.
13. Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, **Di Nicolantonio F**. Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer Res. 2016 Aug 1;76(15):4504-15. doi: 10.1158/0008-5472.CAN-16-0396. Epub 2016 Jun 16. PMID: 27312529.
14. Bartolini A, Cardaci S, Lamba S, Oddo D, Marchiò C, Cassoni P, Amoreo CA, Corti G, Testori A, Bussolino F, Pasqualini R, Arap W, Corà D, **Di Nicolantonio F\***, Marchio S. BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS Mutant Colorectal Cancer. Clin Cancer Res. 2016 Oct 1;22(19):4923-4933. Epub 2016 May 3. doi: 10.1158/1078-0432.CCR-15-2664 PMID: 27143691 **\*co-last and corresponding author**
15. Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, In 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, **Di Nicolantonio F**, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R. A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. Cell. 2016 Apr 7;165(2):317-30. doi: 10.1016/j.cell.2016.02.059. PMID: 27058664
16. Righi L, Vatrano S, **Di Nicolantonio F**, Massa F, Rossi G, Cavazza A, Volante M, Votta A, Izzo S, Lo Iacono M, Ardissone F, Di Maio M, Novello S, Scagliotti GV, Papotti M. Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. J Thorac Oncol. 2016 Apr;11(4):504-15. doi: 10.1016/j.jtho.2016.01.004. Epub 2016 Jan 13. PMID: 26774193
17. Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomatà C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P, De Braud F, Rudà R, Soffietti R, Venesio T, Bardelli A, Wesseling P, de Witt Hamer P, Pietrantonio F, Siena S, Esteller M, Sartore-Bianchi A, **Di Nicolantonio F**. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann Oncol. 2015 Sep;26(9):1994-9. doi: 10.1093/annonc/mdv272. PMID: 26113646
18. Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B, Veronese S, Siena S, Sartore-Bianchi A, Beccuti M, Mottolese M, Linnebacher M, Cordero F, **Di Nicolantonio F**\*, Bardelli A. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat Commun. 2015 Apr 30;6:7002. doi: 10.1038/ncomms8002. PMID: 25926053 **\*co-last and corresponding author** ISI Highly Cited Paper
19. Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, Lieftink C, Bernards R, **Di Nicolantonio F\***, Bardelli A. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep. 2014 Sep 11;8(5):1475-83. PMID: 25199829. **\*co-last and corresponding author**
20. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, **Di Nicolantonio F**, Eggermont AM, Bernards R. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121. Epub 2014 Mar 26. PMID: 24670642 ISI Highly Cited Paper
21. Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A, Gallicchio M**, Di Nicolantonio F**. BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors. Mol Cancer Ther. 2013 Dec;12(12):2950-61. doi: 10.1158/1535-7163.MCT-13-0243. Epub 2013 Oct 9. PMID: 24107445
22. Crowley E, **Di Nicolantonio F**, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013 Aug;10(8):472-84. doi:10.1038/nrclinonc.2013.110. PMID: 23836314. ISI Highly Cited Paper
23. Michieli P, **Di Nicolantonio F**. Targeted therapies: Tivantinib-a cytotoxic drug in MET inhibitor's clothes? Nat Rev Clin Oncol. 2013 Jul;10(7):372-4. PMID: 23712183.
24. **Di Nicolantonio F**, Bardelli A. Mouse Models of Kras-Mutant Colorectal Cancer: Valuable GEMMs for Drug Testing? Clin Cancer Res. 2013 Jun 1;19(11):2794-6. PMID: 23613316
25. Barault L, Lamba S, **Di Nicolantonio F**. Ras Mutations in Cancer. In: eLS 2013. Edited by John Wiley & Sons Ltd:Chichester http://www.els.net/ doi: 10.1002/9780470015902.a0025010, October 2013.
26. Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A, **Di Nicolantonio F**. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer. 2013 Sep 1;133(5):1259-65. doi: 10.1002/ijc.28106. PMID: 23404247
27. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen C.-T , Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, **Di Nicolantonio F**, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer. Nature. 2012 Jun 28;486(7404):532-6. PMID: 22722830 ISI Highly Cited Paper
28. Prahallad A\*, Sun C\*, Huang S\*, **Di Nicolantonio F\***, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012 Jan 26; 483(7387):100-3. PMID: 22281684 **\*co-first authorship, equal contributors** ISI Highly Cited Paper
29. Bottos A, Martini M, **Di Nicolantonio F**, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells in hibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):E353-9. PMID: 22203991
30. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, **Di Nicolantonio F**, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L. A molecularly annotated platform of patient-derived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discovery November 2011 1:508-523; doi:10.1158/2159-8290.CD-11-0109. PMID: 22586653 ISI Highly Cited Paper
31. Zecchin D, **Di Nicolantonio F**. ‘Transfection and DNA-mediated gene transfer’, in Cree IA (ed.) Cancer Cell Culture, Methods Mol Biol. 2011;731:435-50, Springer, New York
32. De Roock W\*, Jonker DJ\*, **Di Nicolantonio F\***, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, , O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Predictive and prognostic effects of KRAS p.G13D mutation in chemotherapy-refractory metastatic colorectal cancer treated with cetuximab . JAMA. 2010 Oct 27;304(16):1812-20. PMID: 20978259 **co-first author \*equal contributors**. ISSN 0098-7484 ISI Highly Cited Paper
33. **Di Nicolantonio F**, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010 Aug 2;120(8):2858-66. PMID: 20664172. ISSN 0021-9738 ISI Highly Cited Paper
34. Mar;5(1):19-28. PMID: 20383783. ISSN 1776-2596. DOI 10.1007/s11523-010-0138-5
35. **Di Nicolantonio F**, Arena S, Gallicchio M, Bardelli A. Isogenic mutant human cells: a new tool for personalized cancer medicine. Cell Cycle. 2010 Jan 1;9(1):20-1. PMID: 20016269
36. Sartore-Bianchi A\*, **Di Nicolantonio F\***, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S. Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer. PLoS ONE 2009;4:e7287. PMID: 19806185 **co-first authorship** **\*equal contributors http://f1000.com/prime/1266960**
37. **Di Nicolantonio F**, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino G, Fantozzi R, Medico E, Bardelli A. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20864-9. PMID: 19106301
38. **Di Nicolantonio F**, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. J Clin Oncol. 2008 Dec 10;26(35):5705-12. PMID: 19001320 ISI Highly Cited
39. Benvenuti S, Sartore-Bianchi A, **Di Nicolantonio F**, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007 Mar 15;67(6):2643-8. PMID: 17363584 ISI Highly Cited Paper
40. **Di Nicolantonio F**, Bardelli A. Kinase mutations in cancer: chinks in the enemy's armour? Curr Opin Oncol. 2006 Jan;18(1):69-76. PMID: 16357567
41. **Di Nicolantonio F**, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, Lamont A, Gulliford T, Hurren J, Yiangou C, Cree IA. Cancer cell adaptation to chemotherapy. BMC Cancer. 2005 Jul18;5(1):78. PMID: 16026610
42. Mercer SJ\*, **Di Nicolantonio F\***, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Bhandari P, Somers SS, Toh SK, Cree IA. Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors. Anticancer Drugs. 2005 Jun;16(5):495-500. PMID: 15846114 **\*equal contributors**
43. **Di Nicolantonio F**, Knight LA, Whitehouse PA, Mercer SJ, Sharma S, Charlton PA, Norris D, Cree IA. The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples. Mol Cancer Ther. 2004 Dec;3(12):1631-7. PMID: 15634657
44. **Di Nicolantonio F**, Knight LA, Glaysher S, Whitehouse PA, Mercer SJ, Sharma S, Mills L, Prin A, Johnson P, Charlton PA, Norris D, Cree IA. Ex vivo reversal of chemoresistance by tariquidar (XR9576). Anticancer Drugs. 2004 Oct;15(9):861-9. PMID: 15457126
45. **Di Nicolantonio F**, Knight LA, Di Palma S, Sharma S, Whitehouse PA, Mercer SJ, Charlton PA, Norris D, Cree IA. Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors. Anticancer Drugs. 2004 Oct;15(9):849-60. PMID: 15457125
46. Sharma S, Neale MH, **Di Nicolantonio F**, Knight LA, Whitehouse PA, Mercer SJ, Higgins BR, Lamont A, Osborne R, Hindley AC, Kurbacher CM, Cree IA. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer. 2003 Jul 3;3(1):19. PMID: 12841853
47. **Di Nicolantonio F**, Neale M, Onadim Z, Hungerford JL, Kingston JL, Cree IA. The chemosensitivity profile of retinoblastoma. in Reinhold U., & Tilgen W. (eds) Springer-Verlag, Berlin. Recent Results Cancer Res. 2003;161:73-80. PMID: 12528800. ISSN 0179-5953
48. **Di Nicolantonio F**, Neale MH, Knight LA, Lamont A, Skailes GE, Osborne RJ, Allerton R, Kurbacher CM, Cree IA. Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer. Anticancer Drugs. 2002 Jul;13(6):625-30. PMID: 12172508